ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback